Malignant mesothelioma of the pleura. The reproducibility of the immunohistological diagnosis

Pathology Research and Practice

Volumn 193, Issue 11-12, 1997, Pages 759-765

  Betta, P G ^a   Andrion, A ^b   Donna, A ^a   Mollo, F ^c   Scelsi, M ^d   Zai, G ^e   Terracini, B ^c   Magnani, C ^c  

^a C Arrigo Children's Hospital   (Italy)

^b Martini Hospital   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e Division of Pathological Anatomy   (Italy)

Author keywords

Diagnostic reproducibility; Immunohistochemistry; Malignant mesothelioma; Observer variation; Pleura

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; VIMENTIN;

ARTICLE; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; OBSERVER VARIATION; PLEURA CANCER; REPRODUCIBILITY;

EID: 0031420575     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(97)80054-4     Document Type: Article

References (26)

1. Andrion A, Magnani C, Betta P-G, Donna A, Mollo F, Scelsi M, Bernardi P, Botta M, Terracini B (1995) Malignant mesothelioma of the pleura: interobserver variability. J Clin Pathol 48: 856-860
2. Attanoos RL, Gibbs AR (1997) Pathology of malignant mesothelioma. Histopathology 30: 403-418
3. Battifora H, McCaughey WTE (1995) Tumors of the serosal membranes. Atlas of Tumor Pathology, 3rd Series. Armed Forces Institute of Pathology, Washington, DC
4. Bedrossian CWM, Bonsib S, Moran C (1992) Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol 9: 124-140
5. Cicchetti DV (1976) Assessing inter-rater reliability for rating scales: resolving some basic issues. Br J Psychiatry 127: 452-456
6. Cicchetti DV, Feinstein AR (1990) High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol 43: 551-558
7. Doglioni C, Dei Tos A, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, Viale G (1996) Calretinm: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 20: 1037-1046
8. Donna A, Betta P-G, Chiodcra PL, Bellingeri D, Libener R, Zorzi F, Tassi GF (1997) Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol 28: 929-937
9. Feinstein AR, Cicchetti DV (1990) High agreement but low kappa: I. The problem of two paradoxes. J Clin Epidemiol 43: 543-549
10. Gotzos V, Vogt P, Celio MR (1996) The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Path Res Pract 192: 137-147
11. Jones JSP (1987) Pathology of the mesothelium. Springer-Verlag, London
12. Kannerstein M, McCaughey WTE, Churg J, Selikoff IJ (1977) A critique of the criteria for the diagnosis of diffuse malignant mesothelioma. Mt Sinai Med J 44: 485-494
13. Leong AS-Y, Vernon-Roberts E (1994) The immunohistochemistry of malignant mesothelioma. Pathol Annu 29 (Pt 2): 157-179
14. Magnani C, Terracini B, Ivaldi C, Botta M, Mancini A, Andrion A (1995) Pleural malignant mesothelioma and non-occupational exposure to asbestos in Casale Monferrato. Italy. Occup Environ Med 52: 362-367
15. McCaughey WTE, Colby TV, Battifora H, Churg A, Corson JM, Greenberg SD, Grimes MM, Hammar S, Roggli V, Unni KK (1991) Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel. Mod Pathol 4: 342-353
16. McDonald AD, McDonald JC (1987) Epidemiology of malignant mesothelioma. In: Antman K, Aisner J (Eds) Asbestos-related malignancy, pp 31-55. Grune & Stratton, Orlando
17. Miettinen M., Kovatich AJ (1995) HBME-1 a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft-tissue and bone tumors. Appl Immunohistochem 3: 115-122
18. Ordóñez NG, Mackay B (1996) The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol 3: 273-293
19. Peralta Soler A, Knudsen KA, Jaurand M-C, Johnson KR, Wheelock MJ, Klein-Szanto AJP, Salazar H (1995) The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 26: 1363-1369
20. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM (1992) Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 23: 107-116
21. Sheibani K (1994) Immunopathology of malignant mesothelioma. Hum Pathol 25: 219-220
22. Skov BG, Lauritzen AF, Hirsch FR, Nielsen HW (1994a) The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis. Histopathology 24: 553-557
23. Skov BG, Lauritzen AF, Hirsch FR, Skov T, Nielsen HW (1994b) Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies. Histopathology 25: 431-437
24. Skov BG, Stahel RA, Hirsch F (1994c) ME1-antibody labelling of primary bronchogenic tumours and extrapulmonary malignancies. Lung Cancer 11: 221-227
25. Swanson PE (1993) Diagnostic immunohistochemistry. A practical primer for the benighted bureaucrat. Am J Clin Pathol 99: 530-532
26. Whitaker D, Shilkin KB (1984) Diagnosis of pleural malignant mesothelioma in life - A practical approach. J Pathol 143: 147-175